Last-Chance treatment offered for advanced urogenital cancers

NCT ID NCT04060628

Summary

This program provided access to an investigational drug called NanoDoce for patients with urogenital cancers who could not join the main clinical trials. It was designed for people who had no other suitable treatment options available. The program is no longer accepting new patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UROGENITAL NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

Explore the condition pages connected to this study.